BOK Financial Private Wealth Inc. Reduces Position in Vertex Pharmaceuticals Incorporated $VRTX

BOK Financial Private Wealth Inc. lowered its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 29.7% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 1,258 shares of the pharmaceutical company’s stock after selling 531 shares during the quarter. BOK Financial Private Wealth Inc.’s holdings in Vertex Pharmaceuticals were worth $560,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of VRTX. Advisor OS LLC raised its holdings in Vertex Pharmaceuticals by 4.4% during the 1st quarter. Advisor OS LLC now owns 543 shares of the pharmaceutical company’s stock valued at $263,000 after acquiring an additional 23 shares during the period. Costello Asset Management INC boosted its holdings in shares of Vertex Pharmaceuticals by 3.6% in the second quarter. Costello Asset Management INC now owns 689 shares of the pharmaceutical company’s stock worth $307,000 after acquiring an additional 24 shares during the period. Kovack Advisors Inc. grew its position in shares of Vertex Pharmaceuticals by 1.9% in the second quarter. Kovack Advisors Inc. now owns 1,280 shares of the pharmaceutical company’s stock valued at $570,000 after purchasing an additional 24 shares in the last quarter. Newman Dignan & Sheerar Inc. raised its stake in shares of Vertex Pharmaceuticals by 3.3% during the 2nd quarter. Newman Dignan & Sheerar Inc. now owns 786 shares of the pharmaceutical company’s stock valued at $350,000 after purchasing an additional 25 shares during the period. Finally, Eastern Bank lifted its holdings in Vertex Pharmaceuticals by 1.6% during the 2nd quarter. Eastern Bank now owns 1,635 shares of the pharmaceutical company’s stock worth $728,000 after purchasing an additional 25 shares in the last quarter. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on VRTX shares. Cantor Fitzgerald reduced their target price on Vertex Pharmaceuticals from $535.00 to $485.00 and set an “overweight” rating for the company in a report on Tuesday, August 5th. JPMorgan Chase & Co. raised their price objective on shares of Vertex Pharmaceuticals from $517.00 to $530.00 and gave the company an “overweight” rating in a research report on Wednesday, October 8th. Royal Bank Of Canada decreased their target price on shares of Vertex Pharmaceuticals from $423.00 to $415.00 and set a “sector perform” rating on the stock in a report on Tuesday, November 4th. Leerink Partners upgraded shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and lowered their target price for the stock from $458.00 to $456.00 in a research note on Thursday, September 25th. Finally, Guggenheim reduced their price target on shares of Vertex Pharmaceuticals from $558.00 to $546.00 and set a “buy” rating for the company in a research report on Wednesday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and twelve have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $489.10.

Vertex Pharmaceuticals Stock Performance

NASDAQ VRTX opened at $409.47 on Monday. Vertex Pharmaceuticals Incorporated has a 52-week low of $362.50 and a 52-week high of $519.88. The company has a fifty day moving average of $404.55 and a 200-day moving average of $429.12. The company has a market capitalization of $103.89 billion, a P/E ratio of 29.27 and a beta of 0.36.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, November 3rd. The pharmaceutical company reported $4.80 EPS for the quarter, beating analysts’ consensus estimates of $4.58 by $0.22. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The business had revenue of $3.08 billion for the quarter, compared to analysts’ expectations of $3.05 billion. During the same quarter in the prior year, the firm earned $4.38 earnings per share. The firm’s revenue was up 11.0% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.